SCHEMBL5535271

SCHEMBL5535271

O=COCCc1ccc(OCCc2ccccc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 4/20 0.61
NPC1 O15118 1/20 0.59
RAB9A P51151 1/20 0.59
LTA4H P09960 1/20 0.55
CA12 O43570 1/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
CA7 P43166 1/20 0.55
CA9 Q16790 1/20 0.55
HPGD P15428 1/20 0.49
GAA P10253 1/20 0.49
S1PR1 P21453 1/20 0.48
S1PR3 Q99500 1/20 0.48
MAOA P21397 1/20 0.48
MAOB P27338 1/20 0.48
DRD2 P14416 1/20 0.47
DRD4 P21917 1/20 0.47
DRD3 P35462 1/20 0.47
PPARG P37231 2/20 0.47
PPARA Q07869 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5541028 0.90 FFAR1 (0.58) FFAR1NPC1RAB9ALTA4HCA12
SCHEMBL5543897 0.90 FFAR1 (0.58) FFAR1LTA4HMAOB
SCHEMBL26583 0.87 CA1 (0.48) FFAR1NPC1RAB9ACA1CA2
Benzene SCHEMBL28219713 0.87 CA1 (0.48) FFAR1NPC1RAB9ACA1CA2
SCHEMBL5545861 0.85 FFAR1 (0.61) FFAR1HPGDS1PR1S1PR3DRD2
SCHEMBL5534673 0.85 FFAR1 (0.61) FFAR1HPGDS1PR1S1PR3DRD2
SCHEMBL5542304 0.85 FFAR1 (0.61) FFAR1HPGDS1PR1S1PR3DRD2
SCHEMBL5541870 0.85 FFAR1 (0.52) FFAR1NPC1RAB9ACA12CA1
Ammonia Solution, Strong SCHEMBL27697032 0.85 CA1 (0.47) FFAR1NPC1RAB9ACA12CA1
SCHEMBL5175852 0.84 FFAR1 (0.63) FFAR1NPC1RAB9ALTA4HCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 FFAR1 105/4885NPC1 2404/4885RAB9A 2824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.